JP6850255B2 - 抗−ｃｄ４７抗体及びその使用 - Google Patents

抗−ｃｄ４７抗体及びその使用 Download PDF

Info

Publication number
JP6850255B2
JP6850255B2 JP2017535814A JP2017535814A JP6850255B2 JP 6850255 B2 JP6850255 B2 JP 6850255B2 JP 2017535814 A JP2017535814 A JP 2017535814A JP 2017535814 A JP2017535814 A JP 2017535814A JP 6850255 B2 JP6850255 B2 JP 6850255B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
cell
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017535814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506964A (ja
JP2018506964A5 (cg-RX-API-DMAC7.html
Inventor
サト アアロン
サト アアロン
スタッフォード ライアン
スタッフォード ライアン
ヤング ジュンハオ
ヤング ジュンハオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2018506964A publication Critical patent/JP2018506964A/ja
Publication of JP2018506964A5 publication Critical patent/JP2018506964A5/ja
Application granted granted Critical
Publication of JP6850255B2 publication Critical patent/JP6850255B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2017535814A 2014-12-30 2015-12-28 抗−ｃｄ４７抗体及びその使用 Expired - Fee Related JP6850255B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098291P 2014-12-30 2014-12-30
US62/098,291 2014-12-30
PCT/US2015/067642 WO2016109415A1 (en) 2014-12-30 2015-12-28 Anti-cd47 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020199312A Division JP2021048858A (ja) 2014-12-30 2020-12-01 抗−ｃｄ４７抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2018506964A JP2018506964A (ja) 2018-03-15
JP2018506964A5 JP2018506964A5 (cg-RX-API-DMAC7.html) 2019-05-23
JP6850255B2 true JP6850255B2 (ja) 2021-03-31

Family

ID=56284963

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017535814A Expired - Fee Related JP6850255B2 (ja) 2014-12-30 2015-12-28 抗−ｃｄ４７抗体及びその使用
JP2020199312A Pending JP2021048858A (ja) 2014-12-30 2020-12-01 抗−ｃｄ４７抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020199312A Pending JP2021048858A (ja) 2014-12-30 2020-12-01 抗−ｃｄ４７抗体及びその使用

Country Status (17)

Country Link
US (2) US10870699B2 (cg-RX-API-DMAC7.html)
EP (1) EP3240569A4 (cg-RX-API-DMAC7.html)
JP (2) JP6850255B2 (cg-RX-API-DMAC7.html)
KR (1) KR102489471B1 (cg-RX-API-DMAC7.html)
CN (1) CN107530421B (cg-RX-API-DMAC7.html)
AU (1) AU2015374301B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017014258A2 (cg-RX-API-DMAC7.html)
CA (1) CA2972604C (cg-RX-API-DMAC7.html)
CL (1) CL2017001736A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017007673A2 (cg-RX-API-DMAC7.html)
EA (1) EA037654B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17041865A (cg-RX-API-DMAC7.html)
HK (1) HK1245154A1 (cg-RX-API-DMAC7.html)
MX (1) MX391051B (cg-RX-API-DMAC7.html)
SG (2) SG11201705310TA (cg-RX-API-DMAC7.html)
WO (1) WO2016109415A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201704467B (cg-RX-API-DMAC7.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037654B1 (ru) 2014-12-30 2021-04-27 Селджин Корпорейшн Анти-cd47-антитела и их применения
BR112017020434A2 (pt) * 2015-05-04 2018-06-26 Pieris Pharmaceuticals Gmbh polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2
BR112019000166A2 (pt) * 2016-07-06 2019-10-01 Celgene Corp anticorpos com baixa imunogenicidade e usos dos mesmos
EP3504234A4 (en) 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES
BR112019008010A2 (pt) 2016-10-20 2019-07-09 I Mab anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
US11352425B2 (en) * 2016-11-08 2022-06-07 Absos, Llc Anti-CD47 antibodies
SG10201913260VA (en) 2016-11-18 2020-03-30 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
US11267885B2 (en) * 2017-01-26 2022-03-08 Zlip Holding Limited CD47 antigen binding unit and uses thereof
WO2018152033A1 (en) * 2017-02-14 2018-08-23 Promab Biotechnologies, Inc. Cd47-car-t cells
MX2019011624A (es) * 2017-03-27 2019-12-05 Celgene Corp Metodos y composiciones para la reduccion de la inmunogenicidad.
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
NZ761568A (en) * 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
JP7256580B2 (ja) * 2017-08-18 2023-04-12 ウルトラヒューマン フォー リミティド 結合剤
KR20220028157A (ko) * 2017-11-10 2022-03-08 아이-맵 바이오파마 유에스 리미티드 Cd47 항체 및 사이토카인을 포함하는 융합 단백질
US11180552B2 (en) 2017-12-01 2021-11-23 Seagen Inc. CD47 antibodies and uses thereof for treating cancer
JP7231641B2 (ja) * 2017-12-04 2023-03-01 北京韓美薬品有限公司 天然抗体様構造を有し、ヘテロ二量体形態の抗ｐｄ－ｌ１／抗ｃｄ４７二重特異性抗体、ならびにその製造方法
SG11202006877PA (en) * 2018-01-24 2020-08-28 Nanjing Legend Biotech Co Ltd Anti-cd47 antibodies that do not cause significant red blood cell agglutination
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
WO2019241732A1 (en) * 2018-06-15 2019-12-19 Accurus Biosciences, Inc. Blocking antibodies against cd47 and methods of use thereof
EP3817769A4 (en) * 2018-07-05 2022-03-30 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
CN110872348B (zh) * 2018-09-03 2021-09-03 长春金赛药业有限责任公司 人源化抗cd47单克隆抗体及其应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20210269522A1 (en) * 2018-10-31 2021-09-02 I-Mab Biopharma Us Limited Novel CD47 Antibodies and Methods of Using Same
KR20210137477A (ko) * 2019-03-06 2021-11-17 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이중기능성 융합 단백질 및 그것의 제약학적 용도
TW202045550A (zh) * 2019-04-05 2020-12-16 美商西建公司 腫瘤選擇性結合cd47之抗體之工程
CN114206912B (zh) 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
CN120775062A (zh) 2019-07-16 2025-10-14 吉利德科学公司 Hiv疫苗及其制备和使用方法
CN112516301B (zh) * 2019-09-17 2025-03-18 鲁南制药集团股份有限公司 一种cd47单克隆抗体的液体制剂及其制备方法
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
KR102866810B1 (ko) * 2019-10-25 2025-09-30 우시 바이올로직스 아일랜드 리미티드 신규한 항-cd47 항체 및 그 용도
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
PH12022552122A1 (en) 2020-02-14 2024-01-29 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
MX2022010515A (es) 2020-02-28 2022-11-14 Tallac Therapeutics Inc Conjugacion mediada por transglutaminasa.
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021262765A1 (en) 2020-06-22 2021-12-30 The Board Of Trustees Of The Leland Stanford Junior University Tsp-1 inhibitors for the treatment of aged, atrophied or dystrophied muscle
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CN114057876B (zh) * 2020-07-31 2025-03-21 百奥泰生物制药股份有限公司 Cd47抗体及其应用
EP4211156A1 (en) * 2020-09-14 2023-07-19 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
CN116685348A (zh) 2020-10-07 2023-09-01 细胞基因公司 淋巴恶性肿瘤病状的双特异性抗体治疗
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN117209608A (zh) * 2020-12-23 2023-12-12 广东菲鹏制药股份有限公司 一种靶向cd47的抗体及其应用
JP2024503822A (ja) * 2021-01-05 2024-01-29 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
KR20230129481A (ko) 2021-01-08 2023-09-08 베이징 한미 파마슈티컬 컴퍼니 리미티드 Cd47과 특이적으로 결합하는 항체 및 그 항원 결합단편
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
ES2999273T3 (en) 2022-03-17 2025-02-25 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
KR20250004824A (ko) 2022-04-21 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Kras g12d 조절 화합물
US20250304694A1 (en) * 2022-06-29 2025-10-02 Korea University Research And Business Foundation Glycosylated fc variants of which binding affinity for human fcgrs is removed
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4551586A1 (en) * 2022-07-10 2025-05-14 MBrace Therapeutics, Inc. Cell-free methods of recombinant antibody production
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
KR20250116736A (ko) 2022-12-09 2025-08-01 화이자 인코포레이티드 Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법
CN120344257A (zh) 2022-12-09 2025-07-18 美国辉瑞有限公司 Cd47阻断剂和抗cd20/抗cd3双特异性抗体组合疗法
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
PT2131860E (pt) 2007-03-20 2014-03-04 Lilly Co Eli Anticorpos antiesclerostina
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2011004847A1 (ja) * 2009-07-07 2011-01-13 一般財団法人化学及血清療法研究所 新規ヒト化抗ヒトα９インテグリン抗体
EP4134095A1 (en) 2009-09-15 2023-02-15 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
BR112013031762A2 (pt) * 2011-06-16 2016-09-13 Novartis Ag proteínas solúveis para utilização como terapêuticos
PT2804617T (pt) * 2012-01-17 2020-09-10 Univ Leland Stanford Junior Reagentes sirp-alfa de alta afinidade
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
SMT201900453T1 (it) 2012-02-06 2019-11-13 Inhibrx Inc Anticorpi anti cd47 e relativi metodi d'uso
KR102276974B1 (ko) * 2013-02-06 2021-07-13 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
WO2014172631A2 (en) * 2013-04-19 2014-10-23 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression
EA037654B1 (ru) 2014-12-30 2021-04-27 Селджин Корпорейшн Анти-cd47-антитела и их применения
JP6885606B2 (ja) 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
CA2999277A1 (en) 2015-09-21 2017-03-30 Surface Oncology, Inc. Anti-cd47 antibodies and methods of use

Also Published As

Publication number Publication date
HK1245154A1 (zh) 2018-08-24
AU2015374301A1 (en) 2017-07-20
JP2018506964A (ja) 2018-03-15
CA2972604A1 (en) 2016-07-07
CN107530421B (zh) 2021-07-20
US20210054070A1 (en) 2021-02-25
ECSP17041865A (es) 2017-08-31
US11787860B2 (en) 2023-10-17
CL2017001736A1 (es) 2018-03-16
ZA201704467B (en) 2019-09-25
EP3240569A1 (en) 2017-11-08
MX2017008819A (es) 2018-03-14
US10870699B2 (en) 2020-12-22
KR20170100652A (ko) 2017-09-04
CA2972604C (en) 2023-07-04
JP2021048858A (ja) 2021-04-01
WO2016109415A1 (en) 2016-07-07
SG11201705310TA (en) 2017-07-28
CN107530421A (zh) 2018-01-02
BR112017014258A2 (pt) 2018-03-06
EA201791485A1 (ru) 2018-02-28
MX391051B (es) 2025-03-21
CO2017007673A2 (es) 2018-01-05
US20170369572A1 (en) 2017-12-28
SG10202007176TA (en) 2020-08-28
AU2015374301B2 (en) 2021-02-11
EA037654B1 (ru) 2021-04-27
KR102489471B1 (ko) 2023-01-18
EP3240569A4 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
JP6850255B2 (ja) 抗−ｃｄ４７抗体及びその使用
JP7237848B2 (ja) 免疫原性の低下のための方法及び組成物
JP7120989B2 (ja) 低免疫原性を有する抗体及びその使用
CA3117429A1 (en) Anti-tim-3 antibodies
CA3156983A1 (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
WO2021214329A1 (en) Composition comprising an ige antibody
CN113454120A (zh) 针对人免疫检查点CEACAM1（CD66a）的拮抗剂抗体及其制剂，试剂盒，和使用方法
CN109414492A (zh) 针对cd81的人源化和嵌合单克隆抗体
US11981745B2 (en) Anti-mesothelin antigen-binding molecules and uses thereof
US20230151090A1 (en) Composition comprising an ige antibody
CN118725133A (zh) 双特异性抗体及其用途
CN120603850A (zh) 抗cmet抗体及使用方法
NZ733261A (en) Anti-cd47 antibodies and uses thereof
EA041917B1 (ru) Антитела с низкой иммуногенностью и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170928

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201201

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201208

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210305

R150 Certificate of patent or registration of utility model

Ref document number: 6850255

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees